| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 6.309 | 16.980 | 17.794 | 26.572 | 29.196 | 22.572 | 32.178 | 29.978 | 33.433 | 40.772 |
| Total Income - EUR | 6.312 | 16.980 | 17.794 | 27.539 | 33.916 | 22.572 | 32.178 | 29.978 | 33.434 | 40.773 |
| Total Expenses - EUR | 8.720 | 11.306 | 15.146 | 25.907 | 27.767 | 21.504 | 31.862 | 29.478 | 32.641 | 38.011 |
| Gross Profit/Loss - EUR | -2.408 | 5.674 | 2.648 | 1.632 | 6.148 | 1.068 | 316 | 500 | 793 | 2.762 |
| Net Profit/Loss - EUR | -2.597 | 5.269 | 2.470 | 1.359 | 5.856 | 849 | 4 | 206 | 454 | 1.563 |
| Employees | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 |
Check the financial reports for the company - S.m.s.c.-Nutridiab S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 632 | 3.026 | 2.222 | 2.312 | 1.575 | 897 | 587 | 297 | 15 | 193 |
| Current Assets | 614 | 4.019 | 5.059 | 7.621 | 9.966 | 11.378 | 6.015 | 1.949 | 2.257 | 1.268 |
| Inventories | 0 | 0 | 0 | 221 | 1.000 | 981 | 0 | 0 | 0 | 0 |
| Receivables | 471 | 1.483 | 3.944 | 2.886 | 4.725 | 2.705 | 2.673 | 0 | 1.589 | 836 |
| Cash | 143 | 2.536 | 1.115 | 4.513 | 4.241 | 7.692 | 3.342 | 1.949 | 668 | 432 |
| Shareholders Funds | -21.949 | -16.451 | -13.703 | -12.092 | -6.001 | -5.039 | -4.923 | -4.732 | -4.263 | -3.129 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 23.195 | 23.496 | 20.984 | 22.025 | 17.542 | 17.314 | 20.024 | 12.911 | 14.674 | 8.663 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - S.m.s.c.-Nutridiab S.r.l.